6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,298 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04287543
(ClinicalTrials.gov)
May 202121/2/2020Melatonin on Clock Genes in Parkinson's DiseaseEffect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Melatonin;Drug: PlacebosInstituto Mexicano del Seguro SocialNULLWithdrawn20 YearsN/AAll0Phase 2/Phase 3Mexico
2NCT02789592
(ClinicalTrials.gov)
July 201631/5/2016Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson DiseaseA Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson DiseaseREM Sleep Behavior Disorder;Parkinson DiseaseDrug: Melatonin PR;Drug: Clonazepam;Drug: Melatonin PR placebo;Drug: Clonazepam placeboSeoul National University HospitalKuhnil Pharmaceutical Co., Ltd.Not yet recruiting30 YearsN/ABoth30Phase 2Korea, Republic of
3NCT03258294
(ClinicalTrials.gov)
January 13, 201620/8/2017Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's DiseaseEffect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled TrialParkinson's DiseaseDrug: Melatonin(Circadin®);Drug: Placebo Oral TabletKIMJisunKuhnil Pharmaceutical Co., Ltd.Enrolling by invitation55 YearsN/AAll82Phase 4NULL
4NCT02768077
(ClinicalTrials.gov)
January 20169/5/2016Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's DiseaseEffect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled TrialParkinson's DiseaseDrug: Melatonin(Circadin®);Drug: PlaceboKuhnil Pharmaceutical Co., Ltd.NULLEnrolling by invitation55 YearsN/ABoth100Phase 4NULL
5EUCTR2014-002697-37-GB
(EUCTR)
15/04/201519/03/2015Study of Melatonin for treatment of Nocturia in PDSingle-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease - Study of Melatonin for treatment of Nocturia in PD Parkinson's DiseaseNocturia
MedDRA version: 17.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Circadin®
Product Name: Melatonin
Product Code: AS2
INN or Proposed INN: Melatonin
University College LondonNULLNot RecruitingFemale: yes
Male: yes
20Phase 2United Kingdom
6NCT02359448
(ClinicalTrials.gov)
April 20154/2/2015Melatonin for Nocturia in Parkinson's DiseaseSingle-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's DiseaseParkinson's Disease;NocturiaDrug: MelatoninUniversity College, LondonNULLNot yet recruiting18 YearsN/ABoth20Phase 2United Kingdom